Amneal Pharmaceuticals, Inc.: Parkinson Disease trials
The registry lists 14 Parkinson Disease studies with Amneal Pharmaceuticals, Inc. as lead sponsor. 1 are open to participants now and 9 have results posted.
Phase 1 1Phase 2 6Phase 3 7Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's DiseaseRecruitingNCT06765668Phase 4
- Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor FluctuationsCompletedNCT03877510Phase 3Results posted
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor FluctuationsCompletedNCT03670953Phase 3Results posted
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseaseCompletedNCT03007888Phase 2Results posted
- Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety StudyCompletedNCT01411137Phase 3Results posted
- A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066CompletedNCT01130493Phase 3Results posted
- An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseaseCompletedNCT01096186Phase 3Results posted
- A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).CompletedNCT00974974Phase 3Results posted
- A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's DiseaseCompletedNCT00880620Phase 3Results posted
- A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-LevodopaCompletedNCT00869791Phase 2Results posted
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's DiseaseCompletedNCT02271503Phase 2
- Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's DiseaseCompletedNCT00279825Phase 2
- Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's DiseaseCompletedNCT00253084Phase 2
- Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's DiseaseCompletedNCT00239564Phase 1/2